An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

Median Time to Onset of High Grade (Grade 3-5) Immune Mediated Adverse Events

Time to onset was calculated from first dosing date to the event onset date. If a participant never experienced the given AE, the participant will be censored at the last contact date.

Time frame: Up to 100 days of the last dose of study drug (Approximately 10 months up to 26 months)

Median Time to Resolution of High Grade (Grade 3-5) Immune Mediated Adverse Events

Time-to resolution of grade 3-5 AE was defined as the longest time from onset to complete resolution or improvement to the grade at baseline among all clustered select AEs in the category experienced by the participant. Events which worsened into grade 5 events (death) or have a resolution date equal to the date of death are considered unresolved. If a clustered AE is considered as unresolved, the resolution date will be censored to the last known date alive.

Time frame: From onset of grade 3-5 IMAEs to resolution of IMAEs (Approximately 4 years and 7 months)

Percentage of Participants Who Receive Immune Modulating Medication for the Immune-Mediated Event (Any Grade)

Immune modulating medication includes corticosteroids, infliximab, cyclophosphamide, Intravenous immunoglobulin (IVIG), and mycophenolate mofetil

Time frame: Up to 100 days of the last dose of study drug (Approximately 3 years and 2 months)

Percentage of Participants Who Receive More Than Equal to (>=) 40 mg Prednisone Equivalents for the Immune-Mediated Event